Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Ferrlecit
Overview
What is Ferrlecit?
Ferrlecit (sodium ferric gluconate complex in sucrose injection), an iron replacement product, is a stable macromolecular complex with an apparent molecular weight on gel chromatography of 289,000 – 440,000 daltons. The macromolecular complex is negatively charged at alkaline pH and is present in solution with sodium cations. The product has a deep red color indicative of ferric oxide linkages. The chemical name is D-Gluconic acid, iron (3+) sodium salt.
The structural formula is considered to be [NaFeO(CHO)(CH0)5]
Each sterile, single-use vial of 5 mL of Ferrlecit for intravenous injection contains 62.5 mg (12.5 mg/mL) of elemental iron as the sodium salt of a ferric ion carbohydrate complex in an alkaline aqueous solution with approximately 20% sucrose w/v (195 mg/mL) in water for injection, pH 7.7 – 9.7.
Each mL contains 9 mg of benzyl alcohol as an inactive ingredient.
What does Ferrlecit look like?
What are the available doses of Ferrlecit?
Ferrlecit is supplied in a single use vial containing 62.5 mg of elemental iron in 5 mL. ()
What should I talk to my health care provider before I take Ferrlecit?
How should I use Ferrlecit?
Ferrlecit is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy.
The dosage of Ferrlecit is expressed in terms of mg of elemental iron. Each 5 mL sterile, single-use vial contains 62.5 mg of elemental iron (12.5 mg/mL).
Do not mix Ferrlecit with other medications, or add to parenteral nutrition solutions for intravenous infusion. The compatibility of Ferrlecit with intravenous infusion vehicles other than 0.9% sodium chloride has not been evaluated. Parenteral drug products should be inspected visually for particulate matter and discoloration before administration, whenever the solution and container permit. If diluted, use immediately.
Ferrlecit treatment may be repeated if iron deficiency reoccurs.
What interacts with Ferrlecit?
Sorry No Records found
What are the warnings of Ferrlecit?
Sorry No Records found
What are the precautions of Ferrlecit?
Sorry No Records found
What are the side effects of Ferrlecit?
Sorry No records found
What should I look out for while using Ferrlecit?
Known hypersensitivity to sodium ferric gluconate or any of its inactive components. ()
What might happen if I take too much Ferrlecit?
The Ferrlecit iron complex is not dialyzable.
No data is available regarding overdose of Ferrlecit in humans. Excessive dosages of Ferrlecit may lead to accumulation of iron in storage sites potentially leading to hemosiderosis. Do not administer Ferrlecit to patients with iron overload [see ].
Individual doses exceeding 125 mg may be associated with a higher incidence and/or severity of adverse events [see ].
Ferrlecit at elemental iron doses of 125 mg/kg, 78.8 mg/kg, 62.5 mg/kg and 250 mg/kg caused deaths in mice, rats, rabbits, and dogs respectively. The major symptoms of acute toxicity were decreased activity, staggering, ataxia, increases in the respiratory rate, tremor, and convulsions.
How should I store and handle Ferrlecit?
Package containing one epinephrine injection, USP auto-injector 0.3 mg: NDC 70385-2009-1Rx onlyPackage containing one epinephrine injection, USP auto-injector 0.3 mg: NDC 70385-2009-1Rx onlyHow SuppliedNDC 0024-2792-10 for vialsFerrlecit is supplied in colorless glass vials. Each sterile, single-use vial contains 62.5 mg of elemental iron in 5 mL for intravenous use, packaged in cartons of 10 vials.How SuppliedNDC 0024-2792-10 for vialsFerrlecit is supplied in colorless glass vials. Each sterile, single-use vial contains 62.5 mg of elemental iron in 5 mL for intravenous use, packaged in cartons of 10 vials.How SuppliedNDC 0024-2792-10 for vialsFerrlecit is supplied in colorless glass vials. Each sterile, single-use vial contains 62.5 mg of elemental iron in 5 mL for intravenous use, packaged in cartons of 10 vials.
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Ferrlecit is used to replete the body content of iron. Iron is critical for normal hemoglobin synthesis to maintain oxygen transport. Additionally, iron is necessary for metabolism and various enzymatic processes.
Non-Clinical Toxicology
Known hypersensitivity to sodium ferric gluconate or any of its inactive components. ()Potential drug interactions between oxiconazole nitrate cream and other drugs have not been systematically evaluated.
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Ferrlecit in post marketing experience. Patients may present with shock, clinically significant hypotension, loss of consciousness, or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Ferrlecit administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Ferrlecit when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions [see ].
In the single-dose, post-marketing, safety study one patient experienced a life-threatening hypersensitivity reaction (diaphoresis, nausea, vomiting, severe lower back pain, dyspnea, and wheezing for 20 minutes) following Ferrlecit administration. Among 1,097 patients who received Ferrlecit in this study, there were 9 patients (0.8%) who had an adverse reaction that, in the view of the investigator, precluded further Ferrlecit administration. These included one life-threatening reaction, six allergic reactions (pruritus x2, facial flushing, chills, dyspnea/chest pain, and rash), and two other reactions (hypotension and nausea). Another 2 patients experienced (0.2%) allergic reactions not deemed to represent drug intolerance (nausea/malaise and nausea/dizziness) following Ferrlecit administration.
The following serious adverse reactions are discussed in greater detail in other sections of the labeling:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).